Pulmonary Fibrosis After Severe COVID-19 Pneumonia

Evaluation of Pulmonary Fibrosis After Severe Interstitial Pneumonia Due to COVID-19 (SARS-CoV-2)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06423560

Acronym

SPIFFERO

Enrollment

Registered

2024-05-21

Start date

2020-03-01

Completion date

2024-05-16

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Pulmonary Fibrosis

Keywords

COVID-19, Pulmonary fibrosis, ARDS, Computed tomography, pulmonary function test

Brief summary

Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma \<50% of total lung volume; and/or (ii) area of lung consolidation \> 10%. All At discharge and after 9 months, all subjects underwent cardiological evaluation, echocardiogram, pulmonary function tests (PFT) both atby 3 and by 12 months after discharge. Chest CT was performed by 12 months after discharge and chest CT. Specifically, the magnitude of pulmonary involvement between baseline and follow-up was considered the primary endpoint of this study. Secondary endpoints of the study were results of respiratory function testing, echocardiographic parametersparameters, and persistence of symptoms.

Interventions

RADIATIONComputed tomography

Follow-up computed tomography at 3-6 months and 12 months

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 * Hospitalization for severe COVID-19 pneumonia * Computed tomography during index hospitalization that showed: (i) normale lung parenchyma \< 50% of total lung volume and/or (ii) parenchymal consolidation \> 10% * Cardiological and pneumological visit, echocardiography and pulmonary function test at 3 and 12 months from hospital discharge * Computed tomography by 12 months from hospital discharge

Exclusion criteria

* Age \< 18 * Absence of previously cited test.

Design outcomes

Primary

Measure	Time frame
The magnitude of pulmonary involvement	12 months

Secondary

Measure	Time frame
results of respiratory function testing	12 months
echocardiographic parameters	12 months
persistence of symptoms	12 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026